Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Journal Title: Нирки - Year 2016, Vol 3, Issue 17
Abstract
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.
Authors and Affiliations
Ron T. Gansevoort, Mustafa Arici, Thomas Benzing
Keywords
Related Articles
- EP ID EP208332
- DOI 10.22141/2307-1257.3.17.2016.76538
- Views 99
- Downloads 0
Modern Philosophy of Knowledge Transfer in Postgraduate Medical Education
.
Examination of a patient with renal pathology and idiopathic fever
Determination of causes of idiopathic fever is a fairly complicated process that in medical practice requires knowledge of the diagnostic algorithms for determining disease etiology accompanied by fever. For a nephrologi...
Drug treatment of urolithiasis using citrate therapy
Urolithiasis - disease, morphological substrate of which is the formation of stones in the urinary tract and related changes in the urinary tract. The disease is characterized by its prevalence and a variety of etiologic...
Correction of Potentially Modified Risk Factors in Hemodialysis Treatment: Standards of Therapy and Individualized Programs of Dialysis
Limitations of possible correction for potentially modified factor the risk of death of patients, who are on renal replacement therapy, by techniques of hemodialysis were studied. The conclusions about the possibility of...
Computer-based exam and clinical thinking: a modern assessment of doctor’s knowledge
The current system of medical exam in postgraduate education and continuing professional development is imperfect, it does not take into account the personal level of knowledge and doctor’s physiological state. This lead...